Cell-replacement research for type 1 diabetes is producing distinct kinds of evidence, not one universal cure. The field includes donor-derived islets, stem-cell-derived islets, attempts to protect cells from the immune system and approaches that have been discontinued. A result for one product cannot be assigned to the others.
This guide follows selected named programs through September 17, 2026. It separates three questions: can the cells produce insulin, can they reduce the person's need for injected insulin, and what is required to keep the cells functioning?
The selected program map
| Program | What it is in the cited record | Dated status or evidence |
|---|---|---|
| Lantidra | Donor-derived pancreatic islets | U.S. approval for a restricted adult population; not a stem-cell-derived product |
| Zimislecel / VX-880 | Stem-cell-derived differentiated islets, studied with immunosuppression | Published early clinical results; developer reported continued enrollment and dosing in August 2026 |
| UP421 | Modified donor-derived islets in an early low-dose study | Developer reported 14-month functional follow-up without immunosuppression |
| SC451 | A separate stem-cell-derived candidate using the related immune-evasion platform | Development plans, not the identity of the cells used in UP421's reported participant |
| VX-264 | Cells combined with a device-based protection approach | Discontinued after missing the reported efficacy endpoint |
The rows come from separate regulator, paper and developer records. They are not a head-to-head efficacy table. 1 2 3 4 5 6
The first divide: where the cells come from
Donor-islet transplantation and stem-cell-derived islet therapy can pursue a similar functional goal while using different sources of cells. Lantidra's label concerns donor-derived cells. Zimislecel's paper concerns fully differentiated cells derived from stem cells. 7 2
The distinction matters to the research question. A successful donor-cell result does not automatically establish the manufacturing consistency, dose or clinical outcome of a stem-cell-derived product. Conversely, a scalable source of cells would not by itself establish that the immune system will permit them to function.
The islet-therapy comparison separates cell source, immune strategy, study population and outcome.
The second divide: replacing cells versus protecting cells
A transplanted cell can be biologically capable of making insulin and still face an immune challenge. NIDDK's transplant explanation describes why immune-suppressing treatment can be part of the care pathway and why it brings risks. 8
That is why a result without immunosuppression receives attention. It addresses a different obstacle from merely producing functional islets. But absence of immunosuppression in one early proof of concept should not be transformed into proof of a complete insulin-free treatment for everyone.
The UP421 and SC451 report makes that distinction explicit. The company says the low-dose UP421 study was not designed to establish reduced external insulin use. 4
What insulin independence actually means
Insulin independence describes an outcome under a study's definition and observation period. It is not automatically lifelong independence, absence of other medication or elimination of the underlying autoimmune condition.
The outcome explainer separates C-peptide production, glucose-control measures, severe hypoglycemia and external insulin use. Those outcomes can inform each other without being interchangeable.
It also explains why a headline percentage must keep its denominator. A result in an analyzed full-dose group is not automatically the result in all enrolled participants or all people with type 1 diabetes. 2
What changed in 2026?
Vertex's August update reported ongoing enrollment and dosing in the zimislecel program and described VX-017 as another investigational candidate moving toward an early study. Sana's later summer update discussed SC451 development. Those are current developer statements about programs, not new randomized efficacy results or marketing approvals. 3 5
Keeping those categories separate is especially important when a paper's publication date, a company's pipeline update and a proposed future filing date appear together in search results.
Why discontinued programs remain in the guide
VX-264's discontinuation is part of the evidence history. It should not disappear because a related approach is promising. It also should not be generalized into failure of every cell-protection strategy. 6
The purpose of this hub is to keep both progress and limitations visible. None of these summaries is a reason to stop prescribed insulin or other care, and this publication does not determine eligibility for transplantation or sell clinical-trial access.
The next useful page depends on the question: use zimislecel for the stem-cell-derived clinical results, Lantidra for the actual U.S. donor-cell approval, or the comparison to understand why their numbers are not interchangeable.
Related strategies: preserve cells or automate insulin
Not every diabetes advance is cell replacement. Tzield’s 2026 indications concern preserving function or delaying progression in specified populations. Artificial pancreas versus islet transplantation separates delivery technology from a biological source of insulin. These articles do not rank treatments for an individual.
Continue with the next question
A1C vs fasting glucose vs OGTT: different tests, different information